Showing 1781-1790 of 3314 results for "".
- Visus Therapeutics to Host First Capital Markets Day in New York Cityhttps://modernod.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/Visus Therapeutics announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue in New York City. During the Capital Markets Day, members of Visus’ leadership team and leading ey
- Fed Unveils Major Expansion of Market Interventionhttps://modernod.com/news/fed-unveils-major-expansion-of-market-intervention/2477439/The Federal Reserve unveiled a major expansion of lending programs Monday that are designed to keep credit markets functioning after they seized up last week, expanding its facilities to include certain types of corporate and municipal debt, according to a Wall Street Journal
- American Academy of Optometry Launches Academy Online: An Online CE Platformhttps://modernod.com/news/american-academy-of-optometry-launches-academy-online-an-online-ce-platform/2480153/The American Academy of Optometry has announced the launch of a new online CE and resource platform, Academy Online. Users can find a collection of session recordings from past annual meetings as well as distance learning credits. This initiative is aimed at assisting optometrists and vision scie
- International Sports Vision Association Announces Leadership Appointments OF NEW EXECUTIVE AND ADVISORY BOARD OFFICERShttps://modernod.com/news/international-sports-vision-association-announces-leadership-appointments-of-new-executive-and-advisory-board-officers/2481491/The International Sports Vision Association (ISVA) announced the appointments of its new Executive and Advisory Board members, effective April 1, 2023. Executive Board Alireza Somji, OD assumes the position of President, succeeding Charles Shidlofsky, OD, FCOV
- Johnson & Johnson Vision Receives FDA Approval for First Drug-Eluting Contact Lens—Acuvue Theravision with Ketotifenhttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-first-drug-eluting-contact-lens-acuvue-theravision-with-ketotifen/2480676/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen), the first drug-eluting contact lens. Each lens contains 19 mcg ketotifen, an antihistamine. Acuv
- Pandemic Will Leave Children With Less Access to Eye Care, New Survey Showshttps://modernod.com/news/pandemic-will-leave-children-with-less-access-to-eye-care-new-survey-shows/2478227/A survey conducted by the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) shows that pediatric specialists are struggling to keep their practices viable in the wake of the shutdown. As a result, ch
- Ophthalmic Leaders Apply Lessons Learned in the Past to COVID-19 Responsehttps://modernod.com/news/looking-to-ophthalmic-leaders/2477601/
- COVID-19: What Can the World Learn From Italy?https://modernod.com/news/covid-19-what-can-the-world-learn-from-italy/2477391/The following perspective about lessons to be learned from the COVID-19 outbreak in Italy appeared in Medscape UK and can be found here. The first case of COVID-19 appeared in Italy on January 30th. A couple of Chinese to
- AAO: Survey Reveals Most Americans Know a Lot Less About Eye Health Than They Think They Dohttps://modernod.com/news/aao-survey-reveals-most-americans-know-a-lot-less-about-eye-health-than-they-think-they-do/2477222/A survey conducted by The Harris Poll has uncovered key gaps in American’s knowledge of eye health, and what they don’t know is putting them at risk of vision loss, according to an AAO news release. With the number of people affected by potentially blinding eye diseases expected to do
- FDA Does Not Approve Bausch Health, Eton’s Pharma’s EM-100 for Allergic Conjunctivitishttps://modernod.com/news/fda-does-not-approve-bausch-health-etons-pharmas-em-100-for-allergic-conjunctivitis/2476731/Eton Pharmaceuticals on Friday said that partner Bausch Health Companies has received a complete response letter from the FDA for its filing seeking approval of the investigational therapy EM-100 to treat ocular itching associated with allergic conjunctivitis. “We